Uterine risk factors (RF) strongly influence survival of women with endometrial cancer, independent of nodal metastasis, according to research published in the March issue of the American Journal of Obstetrics & Gynecology.
FRIDAY, March 18 (HealthDay News) -- Uterine risk factors (RF) strongly influence survival of women with endometrial cancer, independent of nodal metastasis, according to research published in the March issue of the American Journal of Obstetrics & Gynecology.
Nicanor I. Barrena Medel, M.D., from the Columbia University College of Physicians and Surgeons in New York City, and colleagues compared the prognostic value of uterine RF with nodal metastases in 26,967 women with stage I to IIIC endometrial cancer. The participants were stratified into five groups based on the presence or absence of lymph node involvement and the number of RF present (myoinvasion greater than or equal to 50 percent, cervical stromal involvement, and grade 3 histology).
The investigators found that, although both nodal disease and uterine RF strongly influenced survival, the negative prognostic influence of nodal disease was more significant. The five-year overall survival rate of participants with positive node and no RF was 68 percent, compared to 69 percent in participants who were node negative with multiple RF. Node-positive patients with RF had a lower five-year survival rate than node-positive patients with no RF (58 versus 68 percent).
"We noted that uterine RF are important determinants of survival for women with endometrial cancer independent of nodal status," the authors write. "Even in the presence of nodal metastases, uterine RF continue to negatively impact survival."
AbstractFull Text (subscription or payment may be required)
Related Content
Annual Meeting on Women's Cancer (SGO) Oncology – 2011
00g uterine leiomyoma could be successfully operated by modified LAVH using Khampitak uterine screw and forcepsGynecologic Oncology
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More